VolitionRx's latest Q318 results announcement provided an update on the progress across its established R&D projects and added more detail to several newer initiatives. Management explained that the delays in some of the ongoing trials were due to the identified need to upgrade the Nu.Q platform assays to clinical grade. As a result, readouts from the lead trials are now expected throughout 2019 (previously end-2018/early-2019). According to management, upgrade work is underway and a numb
29 Nov 2018
VolitionRx - Platform upgrades and busy 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
VolitionRx - Platform upgrades and busy 2019
VolitionRx's latest Q318 results announcement provided an update on the progress across its established R&D projects and added more detail to several newer initiatives. Management explained that the delays in some of the ongoing trials were due to the identified need to upgrade the Nu.Q platform assays to clinical grade. As a result, readouts from the lead trials are now expected throughout 2019 (previously end-2018/early-2019). According to management, upgrade work is underway and a numb